| Title | Author(s) | Year | View Count |
 | The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years | Brown, DR; Kjaer, SK; Sigurdsson, K; Iversen, OE; Mauricio, HA; Wheeler, CM; Perez, G; Koutsky, LA; Tay, EH; Garcia, P; Ault, KA; Garland, SM; Leodolter, S; Olsson, SE; Tang, GWK; Ferris, DG; Paavonen, J; Steben, M; Bosch, FX; Dillner, J; Joura, EA; Kurman, RJ; Majewski, S; Muñoz, N; Myers, ER; Villa, LL; Taddeo, FJ; Roberts, C; Tadesse, A; Bryan, J; Lupinacci, LC; Giacoletti, KED; Sings, HL; James, M; Hesley, TM; Barra, E | 2009 | 163 |
| The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine hpv types in sexually active women aged 16-26 years | Wheeler, CM; Kjaer, SK; Sigurdsson, K; Iversen, OE; Mauricio, HA; Perez, G; Brown, DR; Koutsky, LA; Tay, EH; García, P; Ault, KA; Garland, SM; Leodolter, S; Olsson, SE; Tang, GWK; Ferris, DG; Paavonen, J; Steben, M; Bosch, FX; Dillner, J; Joura, EA; Kurman, RJ; Majewski, S; Muñoz, N; Myers, ER; Villa, LL; Taddeo, FJ; Roberts, C; Tadesse, A; Bryan, J; Lupinacci, LC; Giacoletti, KED; James, M; Vuocolo, S; Hesley, TM; Barra, E | 2009 | 164 |
| A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions | Kjaer, SK; Sigurdsson, K; Iversen, OE; HernandezAvila, M; Wheeler, CM; Perez, G; Brown, DR; Koutsky, LA; Eng, HT; García, P; Ault, KA; Garland, SM; Leodolter, S; Olsson, SE; Tang, GWK; Ferris, DG; Paavonen, J; Lehtinen, M; Steben, M; Bosch, FX; Dillner, J; Joura, EA; Majewski, S; Muñoz, N; Myers, ER; Villa, LL; Taddeo, FJ; Roberts, C; Tadesse, A; Bryan, J; Maansson, R; Lu, S; Vuocolo, S; Hesley, TM; Saah, A; Barr, E; Haupt, RM | 2009 | 152 |
| Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection | Olsson, SE; Kjaer, SK; Sigurdsson, K; Iversen, OE; HernandezAvila, M; Wheeler, CM; Perez, G; Brown, DR; Koutsky, LA; Tay, EH; García, P; Ault, KA; Garland, SM; Leodolter, S; Tang, GWK; Ferris, DG; Paavonen, J; Lehtinen, M; Steben, M; Bosch, FX; Dillner, J; Joura, EA; Majewski, S; Muñoz, N; Myers, ER; Villa, LL; Taddeo, FJ; Roberts, C; Tadesse, A; Bryan, J; Maansson, R; Vuocolo, S; Hesley, TM; Saah, A; Barr, E; Haupt, RM | 2009 | 168 |
| HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine | Joura, EA; Kjaer, SK; Wheeler, CM; Sigurdsson, K; Iversen, OE; HernandezAvila, M; Perez, G; Brown, DR; Koutsky, LA; Tay, EH; García, P; Ault, KA; Garland, SM; Leodolter, S; Olsson, SE; Tang, GWK; Ferris, DG; Paavonen, J; Lehtinen, M; Steben, M; Bosch, X; Dillner, J; Kurman, RJ; Majewski, S; Muñoz, N; Myers, ER; Villa, LL; Taddeo, FJ; Roberts, C; Tadesse, A; Bryan, J; Lupinacci, LC; Giacoletti, KED; Lu, S; Vuocolo, S; Hesley, TM; Haupt, RM; Barr, E | 2008 | 36 |
| Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials | Joura, EA; Leodolter, S; HernandezAvila, M; Wheeler, CM; Perez, G; Koutsky, LA; Garland, SM; Harper, DM; Tang, GW; Ferris, DG; Steben, M; Jones, RW; Bryan, J; Taddeo, FJ; Bautista, OM; Esser, MT; Sings, HL; Nelson, M; Boslego, JW; Sattler, C; Barr, E; Paavonen, J | 2007 | 51 |
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Garland, SM; HernandezAvila, M; Wheeler, CM; Perez, G; Harper, DM; Leodolter, S; Tang, GWK; Ferris, DG; Steben, M; Bryan, J; Taddeo, FJ; Railkar, R; Esser, MT; Sings, HL; Nelson, M; Boslego, J; Sattler, C; Barr, E; Koutsky, LA | 2007 | 140 |
|
